- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Industry focus on pricing, cost controls this year
Medicare cuts, quality measures and operational scrutiny is high on the list of insurers' other concerns in 2010
Insurers and payers will be watching a number of trends in 2010:
While most seniors will be able to enroll in some kind of MA plan this year, there were reductions in offerings in almost every state and county, according to analysis by Avalere Health. Attrition has been most noticeable with private-fee-for-service plans (PFFS), which face tighter regulatory requirements and payment cuts in the coming year. UnitedHealthcare and Universal American dropped nearly half their PFFS offerings, and several plans have exited the PFFS market completely. This retreat from the MA program is likely to accelerate.
This initiative has raised concerns about healthcare rationing, which was heightened even more just recently by the controversy over mammography screening recommendations from the U.S. Preventive Services Task Force, whose stance influences coverage of screening tests by Medicare and many insurers. Ideally, CER will curb spending on health treatments and services that appear ineffective and help develop practice guidelines accepted by health professionals.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
